Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc.ABOS · Entity 6281 | Chief Operating Officer | January 21, 2026 | January 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acumen Pharmaceuticals, Inc.
Report date January 21, 2026 · Filed January 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 205,092 |
Ending reported balance
After 2026-01-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-21 · Sale · Disposed 2,315 · Balance 205,554 F1: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024. F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7600 to $1.8700. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2026-01-22 · Sale · Disposed 462 · Balance 205,092 F1: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024.
F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7600 to $1.8700. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2026 Filed Jan 23, 2026 23:10 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 462 | $1.84 | $850.08 |
DisclosureSEC source: 0001628280-26-003344 · wk-form4_1769209803.xml · nonDerivative · entry 2 Barton Russell · CIK 0001867418 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,092 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 23:10 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 2,315 | $1.81 | $4,180.89 |
DisclosureSEC source: 0001628280-26-003344 · wk-form4_1769209803.xml · nonDerivative · entry 1 Barton Russell · CIK 0001867418 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,554 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7600 to $1.8700. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 23:30 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantEmployee Stock Option (right to buy) · Derivative | 126,900 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001628280-26-002958 · wk-form4_1769038220.xml · derivative · entry 2 Barton Russell · CIK 0001867418 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,900 Underlying: Common Stock · 126,900 shares Expires 2036-01-16 F2 · derivative.exercise_date: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 23:30 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 84,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-002958 · wk-form4_1769038220.xml · nonDerivative · entry 1 Barton Russell · CIK 0001867418 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207,869 F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 23:52 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 3,530 | $1.86 | $6,561.56 |
DisclosureSEC source: 0001628280-26-001897 · wk-form4_1768261937.xml · nonDerivative · entry 1 Barton Russell · CIK 0001867418 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,269 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 25, 2025. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.8000 to $1.9500. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 02:30 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 1,700 | $1.99 | $3,378.07 |
DisclosureSEC source: 0001628280-26-001261 · wk-form4_1767839412.xml · nonDerivative · entry 3 Barton Russell · CIK 0001867418 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,799 F4 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 25, 2025. F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9550 to $2.0200. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 02:30 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 3,618 | $1.97 | $7,114.44 |
DisclosureSEC source: 0001628280-26-001261 · wk-form4_1767839412.xml · nonDerivative · entry 2 Barton Russell · CIK 0001867418 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,499 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9400 to $1.9900. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 05, 2026 Filed Jan 8, 2026 02:30 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 4,000 | $1.96 | $7,832.40 |
DisclosureSEC source: 0001628280-26-001261 · wk-form4_1767839412.xml · nonDerivative · entry 1 Barton Russell · CIK 0001867418 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,117 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9100 to $1.9800. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 22:14 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 2,914 | $1.61 | $4,692.12 |
DisclosureSEC source: 0001576885-25-000031 · wk-form4_1737670478.xml · nonDerivative · entry 1 Barton Russell · CIK 0001867418 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,117 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2024. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.6100 to $1.6150. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 00:55 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantEmployee Stock Option (right to buy) · Derivative | 74,700 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001576885-25-000013 · wk-form4_1736297739.xml · derivative · entry 3 Barton Russell · CIK 0001867418 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,700 Underlying: Common Stock · 74,700 shares Expires 2035-01-06 F4 · derivative.exercise_date: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 00:55 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 49,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001576885-25-000013 · wk-form4_1736297739.xml · nonDerivative · entry 2 Barton Russell · CIK 0001867418 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,031 F3 · shares: Represents an RSU award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 03, 2025 Filed Jan 8, 2025 00:55 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 7,636 | $1.86 | $14,225.10 |
DisclosureSEC source: 0001576885-25-000013 · wk-form4_1736297739.xml · nonDerivative · entry 1 Barton Russell · CIK 0001867418 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,231 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2024. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7700 to $1.9000. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 18, 2024 Filed Jan 20, 2024 00:04 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | SaleCommon Stock | 2,833 | $3.73 | $10,555.19 |
DisclosureSEC source: 0001576885-24-000024 · wk-form4_1705709048.xml · nonDerivative · entry 1 Barton Russell · CIK 0001867418 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,867 F1 · shares: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2023. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $3.7250 to $3.7300. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:23 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantEmployee Stock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001576885-24-000013 · wk-form4_1704403365.xml · derivative · entry 2 Barton Russell · CIK 0001867418 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2034-01-01 F2 · derivative.exercise_date: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:23 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 73,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001576885-24-000013 · wk-form4_1704403365.xml · nonDerivative · entry 1 Barton Russell · CIK 0001867418 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,700 F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 21:19 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantEmployee Stock Option (right to buy) · Derivative | 120,200 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0001209191-23-003731 · doc4.xml · derivative · entry 2 Barton Russell · CIK 0001867418 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,200 Underlying: Common Stock · 120,200 shares Expires 2033-01-16 F2 · derivative.exercise_date: The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 21:19 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantCommon Stock | 26,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-003731 · doc4.xml · nonDerivative · entry 1 Barton Russell · CIK 0001867418 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,700 F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:18 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantEmployee Stock Option (right to buy) · Derivative | 135,000 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001209191-22-004415 · doc4.xml · derivative · entry 1 Barton Russell · CIK 0001867418 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2032-01-19 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest and become exercisable on January 19, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest and become exercisable each month thereafter, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.